The TBII (Thyrotropin-Binding Inhibitory Immunoglobulin) test is a specialized diagnostic assay designed to measure the levels of TBII in the blood. TBII are autoantibodies that can interfere with the normal function of the thyroid gland by inhibiting the binding of thyrotropin (TSH) to its receptor, potentially leading to conditions such as Graves' disease, an autoimmune disorder characterized by hyperthyroidism. This test plays a crucial role in diagnosing and managing thyroid-related autoimmune conditions by providing valuable insights into the presence and activity level of these inhibitory immunoglobulins.
In the United Arab Emirates, DNA Labs UAE offers the TBII test, ensuring high-quality diagnostic services. The cost of the test at DNA Labs UAE is set at 2780 AED, reflecting the sophisticated nature of the assay and the detailed, reliable results it provides. Patients seeking to understand the underlying causes of their thyroid dysfunction or to monitor the progress of their treatment for autoimmune thyroid conditions may find this test particularly useful. Conducted in a state-of-the-art facility, the TBII test at DNA Labs UAE represents an important tool in the comprehensive evaluation of thyroid health and autoimmune disorders.
The Multiple Sclerosis Panel 2 Test is a specialized diagnostic examination offered by DNA Labs UAE, designed to provide comprehensive insights into genetic markers associated with Multiple Sclerosis (MS), a chronic autoimmune disease that affects the central nervous system. Priced at 2750 AED, this test is an advanced tool for individuals seeking an in-depth analysis of their genetic predisposition to MS. Through a meticulous examination of specific DNA segments, the test aims to identify variations that may indicate a higher risk of developing this condition. Conducted in the state-of-the-art facilities of DNA Labs UAE, the test results can aid healthcare professionals in devising personalized management and treatment plans, potentially improving patient outcomes by addressing the disease proactively.
The "Aspirin Resistance 11-Dehydrothromboxane B2 Test" is a specialized diagnostic tool designed to assess the effectiveness of aspirin therapy in individuals. Aspirin is commonly prescribed to prevent blood clots, which can lead to heart attacks and strokes, by inhibiting the production of thromboxane, a molecule that plays a crucial role in clot formation. However, some individuals may not respond to aspirin treatment as expected, a condition known as aspirin resistance.
This test specifically measures the levels of 11-Dehydrothromboxane B2 in the urine, a stable metabolite of thromboxane, to evaluate how well aspirin is inhibiting thromboxane production in the body. Elevated levels of this metabolite may indicate that aspirin is not effectively reducing clot formation risk, suggesting the need for alternative therapeutic strategies.
Offered by DNA Labs UAE, the test is priced at 2750 AED. Conducting this test can be crucial for individuals on aspirin therapy, especially those at high risk for cardiovascular events, to ensure that they are receiving the most effective treatment for their condition. By tailoring therapy based on the test results, healthcare providers can better manage the risk of heart attacks and strokes in their patients.
The "Cultured AFB Antitubercular DST Rapid 11 Drugs Panel Test" is a sophisticated diagnostic procedure available at DNA Labs UAE, designed to rapidly identify the drug susceptibility of Mycobacterium tuberculosis complex (MTBC) isolates. This test is crucial for the management of tuberculosis (TB), as it helps in determining the most effective drug regimen for treating the infection, especially in cases of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB).
The panel covers a comprehensive range of 11 drugs, ensuring a broad assessment of the bacterium's resistance profile. By analyzing cultured samples of the AFB (Acid-Fast Bacilli), this test can accurately pinpoint which antitubercular drugs the TB strain is resistant to, thereby guiding healthcare professionals in tailoring the most appropriate and effective treatment plan for the patient.
Priced at 2710 AED, the test represents a significant investment in the accurate and expedited management of tuberculosis, a disease that continues to pose a significant public health challenge globally. Conducted at the state-of-the-art facilities of DNA Labs UAE, patients and healthcare providers can expect reliable and timely results, contributing to better treatment outcomes and the containment of TB spread.
The Immunohistochemistry PDL1 SP142 Test is a specialized diagnostic procedure performed to evaluate the expression of the Programmed Death-Ligand 1 (PD-L1) protein in cancer cells. This test is particularly significant in the context of certain cancers, such as non-small cell lung cancer (NSCLC), as it helps in determining the suitability of patients for immunotherapy treatments targeting the PD-1/PD-L1 pathway. The SP142 clone is utilized in this assay to specifically detect PD-L1 expression, which can be pivotal in guiding therapeutic decisions and predicting patient response to specific immunotherapies.
At DNA Labs UAE, this test is offered at a cost of 2700 AED. The laboratory is equipped with advanced technologies and staffed by experienced professionals to ensure accurate and reliable results. Conducting the Immunohistochemistry PDL1 SP142 Test at DNA Labs UAE involves a meticulous process of preparing and analyzing tissue samples, with results that can significantly impact treatment planning and outcomes for patients with certain types of cancer.
The "All PCR Panel Cytogenetics and PCR BCR-ABL TEL-AML1 MLL E2A Test" is a comprehensive diagnostic assay performed at DNA Labs UAE, designed to detect and characterize genetic abnormalities associated with various hematological malignancies, including leukemias and lymphomas. This test employs Polymerase Chain Reaction (PCR) technology, a highly sensitive and specific method, to amplify and detect specific genetic sequences of interest. The panel includes markers for several critical translocations and gene rearrangements such as BCR-ABL, which is associated with Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL); TEL-AML1, related to childhood ALL; MLL gene rearrangements found in various types of leukemia; and E2A gene rearrangements.
This comprehensive genetic test is pivotal for accurate diagnosis, prognosis, and in guiding targeted therapy decisions for patients with suspected or confirmed hematological malignancies. The cost of the test is 2300 AED, reflecting the intricate technology and expertise required to perform the analysis. Conducted at DNA Labs UAE, a facility known for its state-of-the-art technology and high standards of genetic testing, patients and healthcare providers can expect reliable and clinically relevant results that are crucial for effective disease management.
The BCR-ABL1 Kinase Domain Mutation Analysis IRMA Test is a highly specialized diagnostic procedure offered by DNA Labs UAE, designed to detect mutations within the kinase domain of the BCR-ABL1 gene. This gene is significant because its mutations are closely associated with chronic myeloid leukemia (CML) and some forms of acute lymphoblastic leukemia (ALL). The presence and type of mutations can influence the patient's response to tyrosine kinase inhibitors (TKIs), which are a class of medications used in the treatment of these leukemias.
The test involves analyzing the patient's genetic material to identify any mutations in the BCR-ABL1 kinase domain, providing critical information for personalized treatment planning. It is particularly valuable for patients who are experiencing resistance to TKI therapy, as it helps in selecting the most effective treatment strategy moving forward.
At DNA Labs UAE, the BCR-ABL1 Kinase Domain Mutation Analysis IRMA Test is priced at 2200 AED. This cost reflects the sophisticated technology and expertise required to accurately detect and interpret the specific genetic mutations. For patients and healthcare providers, this test represents a crucial step in tailoring leukemia treatment to the individual's genetic profile, potentially improving treatment outcomes and quality of life.
Spinal Muscular Atrophy (SMA) is a genetic disorder characterized by weakness and wasting in muscles used for movement. It occurs due to the loss of nerve cells called motor neurons in the spinal cord and the brainstem, leading to severe and progressive muscle wasting and weakness. Early detection and intervention can significantly impact the quality of life, making carrier screening an essential step for individuals planning to start a family.
The SMA Carrier Screening Test is a genetic test designed to identify individuals who carry a copy of the mutated gene responsible for Spinal Muscular Atrophy. Being a carrier means that the individual does not typically show symptoms of SMA but has a chance of passing the gene to their offspring. The test is particularly recommended for those with a family history of SMA or those in ethnic groups with a higher carrier frequency.
At DNA Labs UAE, the SMA Carrier Screening Test is available for individuals seeking to understand their carrier status. The test cost is 2250 AED and involves a simple and non-invasive procedure. DNA Labs UAE employs state-of-the-art genetic testing technologies to ensure accurate and reliable results, providing crucial information for family planning decisions. The facility is committed to maintaining confidentiality and providing professional genetic counseling to help interpret the test results and understand the potential implications for family planning.
Spinal Muscular Atrophy (SMA) Screening Prenatal Test is a crucial genetic test conducted to determine the risk of a fetus developing Spinal Muscular Atrophy, a severe genetic disorder that affects muscle control and strength. This test is especially important for expectant parents with a family history of SMA or those who want to assess the risk of their child inheriting this condition. The test analyzes the DNA of the fetus to detect mutations in the SMN1 gene, which are indicative of SMA. Conducted at DNA Labs UAE, a leading facility in genetic testing, the SMA Screening Prenatal Test ensures high accuracy and reliability. The cost of the test is 2250 AED, a valuable investment for parents seeking peace of mind regarding their child's genetic health. Early detection through this prenatal screening allows for better preparation and early intervention strategies to manage the condition effectively.
The "Chlamydia Trachomatis, N. Gonorrhea, M. Genitalium, Treponema Pallidum Multiplex Detection and Differentiation RNA Detection Qualitative Test" is a sophisticated diagnostic tool designed to identify and distinguish between the RNA of four major sexually transmitted infections (STIs): Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, and Treponema pallidum, the bacterium responsible for syphilis. This qualitative test employs advanced RNA detection techniques to accurately diagnose the presence of these pathogens in a single sample, offering a comprehensive screening approach for individuals at risk of these infections.
Performed at DNA Labs UAE, a leading facility in genetic and molecular diagnostics, this test is priced at 2600 AED. The lab utilizes state-of-the-art technology to ensure high sensitivity and specificity, providing reliable results that are crucial for the appropriate treatment and management of these infections. Early detection through such multiplex testing is vital for preventing complications associated with these STIs and for controlling their spread within populations.
